Current treatment options for myeloma

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 7, 2005, Pages 1127-1142

  Terpos, Evangelos ^a,b   Rahemtulla, Amin ^b   Dimopoulos, Meletios Athanassios ^c  

^a 251 General Air Force Hospital   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bortezomib; Chemotherapy; Multiple myeloma; Stem cell transplantation; Thalidomide

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 AZA 2' DEOXYCYTIDINE; AE 941; ALPHA INTERFERON; AMGN 0007; ARSENIC TRIOXIDE; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; LENALIDOMIDE; LONAFARNIB; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBLIMERSEN; OSTEOPROTEGERIN; PAMIDRONIC ACID; PREDNISOLONE; PRINOMASTAT; SCIO 469; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VATALANIB; VINCRISTINE; VORINOSTAT; ZOLEDRONIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRADYCARDIA; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; HYPOTHYROIDISM; INFECTION; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALAISE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PROGNOSIS; REVIEW; RISK FACTOR; SOMNOLENCE; SURVIVAL RATE; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VOMITING; XEROSTOMIA;

AGE FACTORS; ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DOXORUBICIN; HUMANS; MELPHALAN; MULTIPLE MYELOMA; OSTEOLYSIS; PREDNISOLONE; PYRAZINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 21844457396     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.7.1127     Document Type: Review

References (105)

1. The International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. (2003) 121(5):749-757.
2. BLADE J, VESOLE DH, GERTZ M: High-dose therapy in multiple myeloma. Blood (2003) 102(10):3469-3470.
3. HE Y, WHEATLEY K, CLARK O, GLASMACHER A, ROSS H, DJULBEGOVIC B: Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst. Rev. (2003) 1:CD004023.
4. WEBER DM, DIMOPOULOS MA, MOULOPOULOS LA et al.: Prognostic features of asymptomatic multiple myeloma. Br J. Haematol. (1997) 97(4):810-814.
5. MARIETTE X, ZAGDANSKI AM, GUERMAZI A et al.: Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br. J. Haematol. (1999) 104(4):723-729.
6. ALEXANIAN R, HAUT A, KHAN AU et al.: Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 208(9):1680-1685.
7. BELCH A, SHELLEY W, BERGSAGEL D et al.: A randomised trial of maintenance vs. no maintenance melphalan and prednisolone in responding multiple myeloma patients. Br. J. Cancer. (1988) 57(1):94-99.
8. CROWLEY J, JACOBSON J, ALEXANIAN R: Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience. Semin. Hematol. (2001) 38(3):203-208.
9. ALEXANIAN R, DIMOPOULOS M: The treatment of multiple myeloma. N. Engl. J. Med. (1994) 330(7):484-489.
10. DIMOPOULOS MA, POULI A, ZERVAS K et al.: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann. Oncol. (2003) 14(7):1039-1044.
11. RAJE N, POWLES R, KULKARNI S et al.: A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br. J. Haematol. (1997) 97(1):153-160.
12. AITCHISON RG, REILLY IA, MORGAN G, RUSSELL NH: Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br. J. Cancer (1990) 61(5):765-766.
13. ALEXANIAN R, DIMOPOULOS MA, DELASALLE K, BARLOGIE B: Primary dexamethasone treatment of multiple myeloma. Blood (1992) 80(4):887-890.
14. COOK G, SHARP RA, TANSEY P, FRANKLIN IM: A Phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br. J. Haematol. (1996) 93(4):931-934.
15. MACLENNAN IC, CHAPMAN C, DUNN J, KELLY K: Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet (1992) 339(8787):200-205.
16. Myeloma Trialists' Collobarative Group: Combination chemotherapy vs. melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. (1998) 16(12):3832-3842.
17. FRITZ E, LUDWIG H: Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann. Oncol. (2000) 11(11):1427-1436.
18. The Myeloma Trialists' Collobarative GroupP: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br. J. Haematol. (2001) 113(4):1020-1034.
19. WISLOFF F, HJORTH M, KAASA S, WESTIN J: Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br. J. Haematol. (1996) 94(2):324-332.
20. WISLOFF F, GULBRANDSEN N: Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol. (2000) 39(7):809-813.
21. 2 + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of Intergroup trial S9321 in the context of IFM90 and MRC VII trials. Blood (2004) 104(11):156a-157a (Abstract).
22. ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. (1996) 335(2):91-97.
23. CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. (2003) 348(19):1875-1883.
24. PALUMBO A, BRINGHEN S, PETRUCCI MT et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 104 (10)3052-3057.
25. FERMAND JP, RAVAUD P, KATSAHIAN S et al.: High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age. Blood (1999) 94(Suppl. 1):396a (Abstract).
26. BLADE J, SUREDA A, RIBERA JM et al.: High-dose therapy/ autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months. Blood (2003) 102(11):42a (Abstract).
27. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intregroupe Francophone do Myelome 9502 randomized trial. Blood (2002) 99(3):731-735.
28. FERMAND JP, RAVAUD P, CHEVRET S et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomised clinical trial. Blood (1998) 92(9):3131-3136.
29. TERPOS E, APPERLEY JF, SAMSON D et al.: Amologous stem cell transplantation in multiple myeloma: improved survival in non-secretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant (2003) 31(3):163-170.
30. STEWART AK, VESCIO R, SCHILLER G et al.: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin. Oncol. (2001) 19(17):3771-3779.
31. ALEGRE A, DIAZ-MEDIAVILLA J, SAN-MIGUEL J et al.: Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM and PETHEMA. Bone Marrow Transplant (1998) 21(2):133-140.
32. MAJOLINO I, VIGNETTI M, MELONI G et al.: Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica (1999) 84(9):844-852.
33. BARLOGIE B, SHAUGHNESSY J, TRICOT G et al.: Treatment of multiple myeloma. Blood (2004) 103 (1):20-32.
34. FASSAS AB, SPENCER T, SAWYER J et al.: Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. Haematol. (2002) 118(4):1041-1047.
35. SHAUGHNESSY J, JACOBSON J, SAWYER J et al.: Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long term survival in myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood (2003) 101(10)3849-3856.
36. JACOBSON J, BARLOGIE B, SHAUGHNESSY J et al.: MDS-cype abnormalities with myeloma signature karyotype: only 13% 1-year survival despite tandem transplants. Br. J. Haematol. (2003) 122(3):430-440.
37. FACON T, AVET-LOISEAU H, GUILLERM G et al.: Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood (2001) 97(6):1566-1571.
38. SHAUGHNESSY J, TIAN E, SAWYER J et al.: Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br. J. Haematol. (2003) 120(1):44-52.
39. PORRATA LF, GERTZ MA, GEYER SM et al.: The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia (2004) 18(6):1085-1092.
40. POLITOU M, TERPOS E, CRAWLEY D et al.: Pre-transplant VEGF levels in multiple myeloma are predictive for progression free survival. Hematol. J. (2004) 5(Suppl. 2):S13 (Abstract).
41. HAROUSSEAU JL, SHAUGHNESSY J Jr, RICHARDSON P: Multiple myeloma. Hematology (2004):237-256.
42. ATTAL M, HAROUSSEAU JL, FACON T et al.: Single versus double autologous stem cell transplantation for multiple myeloma. N. Engl. J. Med. (2003) 349(26):2495-2502.
43. CAVO M, CELLINI C, ZAMAGNI E et al.: Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood (2004) 104(11):155a-156a (Abstract).
44. SONNEVELD P, VAN DER HOLT B, SEGEREN C et al.: Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study Hovon 24 MM. Blood (2004) 104(11):271a-272a (Abstract).
45. FERMAND JP, ALBERTI C, MAROLLEAU JP: Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma. Hematol. J. (2003) 4(Suppl. 1):S59 (Abstract).
46. MORRIS C, IACOBELLI S, BRAND R et al.: Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J. Ciin. Oncol. (2004) 22(9):1674-1681.
47. LEE CK, BARLOGIE B, FASSAS A et al.: Third autotransplant for the management of 98 patients among 1358 who had received prior tandem autotransplants: benefit apparent when 2nd to 3rd transplant interval exceeds 3 years. Blood (2004) 104(11):157a (Abstract).
48. REECE DE, BREDESON C, PEREZ WS et al.: Autologous stem cell transplantation in multiple myeloma patients <60 vs. ≥60 years of age. Bone Marrow Transplant. (2003) 32(12):1135-1143.
49. PALUMBO A, BRINGHEN S, PETRUCCI MT et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 104(10):3052-3057.
50. BADROS A, BARLOGIE B, SIEGEL E et al.: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br. J. Haematol. (2001) 114(4):822-829.
51. LEE CK, ZANGARI M, BARLOGIE B et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. (2004) 33(8):823-828.
52. SAN MIGUEL JF, LAHUERTA JJ, GARCIA-SANZ R et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol. J. (2000) 1(1):28-36.
53. LOKHORST HM, WU K, VERDONCK LF et al.: The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood (2004) 103(11):4362-4364.
54. GAHRTON G, SVENSSON H, CAVO M et al.: Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. (2001) 113(1):209-216.
55. BJORKSTRAND B, LJUNGMAN P, SVENSSON H et al.: Allogenic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood (1996) 88(12):4711-4718.
56. ALYEA E, WELLER E, SCHLOSSMAN R et al.: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. (2003) 32(12):1145-1151.
57. The UK Myeloma Forum Guidelines Working Group: Guidelines on the diagnosis and management of multiple myeloma. Br. Haematol. (2001) 115(3):522-540.
58. CORRADINI P, VOENA C, TARELLA C et al.: Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. (1999) 17(1):208-215.
59. DURIE BG, KYLE RA, BELCH A et al.: Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Haematol. J. (2003) 4(6):379-398.
60. LE BLANC R, MONTMINY-METIVIER S, BELANGER R et al.: Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. (2001) 28(9):841-848.
61. ALYEA E, WELLER E, SCHLOSSMAN R et al.: T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood (2001) 98(4):934-939.
62. PEREZ-SIMON J, CABALLERO D, MATEOS M, MIGUEL JS: Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk. Lymphoma. (2004) 45(9):1725-1729.
63. KROGER N, SCHWERDTFEGER R, KIEHL M et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood (2002) 100(3):755-760.
64. MALONEY DG, MOLINA AJ, SAHEBI F et al.: Allografting with non myeloabaltive conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood (2003) 102(9):3447-3454.
65. KROGER N, SCHILLING G, EINSELE H et al.: Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood (2004) 103(11):4056-4061.
66. GILES FJ: Current therapy of refractory multiple myeloma. Stem Cells (1995) 13(Suppl. 2):88-105.
67. RAJKUMAR SV, FONSECA R, LACY MQ et al.: Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. (1999) 23(12):1267-1272.
68. ALEXANIAN R, DIMOPOULOS MA, HESTER J, DELASALLE K, CHAMPLIN R: Early myeloablative therapy for multiple myeloma. Blood (1994) 84(12):4278-4282.
69. DIMOPOULOS MA, WEBER D, KANTARJIAN H, DELASALLE KB, ALEXANIAN R: HyperCVAD for VAD-resistant multiple myeloma. Am. J. Hematol. (1996) 52(2):77-81.
70. PARAMESWARAN R, GILES C, BOOTS M et al.: CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br. J. Haematol. (2000) 109(3):571-575.
71. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341(21):1565-1571.
72. BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood (2001) 98(2):492-494.
73. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. (2001) 12(7):991-995.
74. ANAGNOSTOPOULOS A, WEBER D, RANKIN K, DELASALLE K, ALEXANIAN R: Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. (2003) 121(5):768-771.
75. CAVENAGH JD, OAKERVEE H: Thalidomide in multiple myeloma: current status and future prospects. Br. J. Haematol. (2003) 120(1):18-26.
76. LEE CK, BARLOGIE B, MUNSHI N et al.: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. Oncol. (2003) 21(14):2732-2739.
77. DIMOPOULOS MA, HAMILOS G, ZOMAS A et al.: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously created patients with multiple myeloma. Hematol. J. (2004) 5(2):112-117.
78. RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20(21):4319-4323.
79. WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21(1):16-19.
80. RAJKUMAR SV, BLOOD E, VESOLE DH, SHEPARD R, GREIPP PR: Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood (2004) 104(11):63a (Abstract).
81. ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E et al.: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann. Oncol. (2004) 15(1):134-138.
82. PALUMBO A, BERTOLA A, MUSTO P et al.: A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interin analysis. Blood (2004) 104(11):63a (Abstract).
83. DIMOPOULOS MA, REPOUSSIS P, TERPOS E et al.: Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≥ 75 years of age. Blood (2004) 104(11):414a Abstract).
84. DIMOPOULOS MA, ELEUTHERAKIS PAPAIAKOVOU V: Adverse effects of thalidomide administration in patients with neoplastic diseases. Am. J. Med. (2004) 117(7):508-515.
85. HIDESHIMA T, CHAUHAN D, HAYASHI T et al.: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene (2003) 22(52):8386-8393.
86. MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Ac. Sci. USA (2002) 99(22):14374-14379.
87. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609-2617.
88. JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. (2004) 127(2):165-172.
89. RICHARDSON P, SONNEVELD P, SCHUSTER MW et al.: Bortezomib vs. dexamethasone in relapsed multiple myeloma: a Phase 3 randomized study. Proc. Am. Soc. Clin. Oncol. (2004) 23:558 (Abstract).
90. BERENSON J, YANG H, SWIFT R et al.: Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood (2004) 104 (11):64a (Abstract).
91. ORLOWSKI RZ, VOORHEES PM, GARCIA RA et al.: Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood (2005) (In press).
92. JAGANNATH S, BRIAN D, WOLF JL et al.: A Phase 2 study of bortezomib as first line therapy in patients with multiple myeloma. Blood (2004) 104(11):98a-99a (Abstract).
93. ALEXANIAN R, WANG LM, WEBER DM, DELASALLE KB: VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood (2004) 104(11):64a (Abstract).
94. BARLOGIE B, HOLLMIG K, ZANGARI M et al.: Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating Velcade into remission induction with DT-PACE: early resuhs regarding efficacy, PBSC mobilization and toxicities. Blood (2004) 104(11):156a (Abstract).
95. TERPOS E, RAHEMTULLA A: Bisphosphonate treatment for multiple myeloma. Drugs Today (2004) 40(1):29-40.
96. DJULBEGOVIC B, WHEATLEY K, ROSS J et al.: Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. (2002) 3:CD003188.
97. BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clin. Oncol. clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20(17):3719-3736.
98. TERPOS E, POLITOU M, RAHEMTULLA A: New insights into the pathophysiology and management of bone disease in multiple myeloma. Br. J. Haematol. (2003) 123(5):758-769.
99. MUSTO P, FALCONE A, SANPAOLO G et al.: Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk. Lymphoma (2003) 44(9):1545-1548.
100. CAPARROTTI G, CATALANO L, FEO C et al.: Perspective study on pamidronate in stage I multiple myeloma. Hematol. J. (2003) 4(6):459-460.
101. RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100(9):3063-3067.
102. HUSSEIN MA, KARAM MA, BRAND C et al.: Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid® (DVd-R): a phase I/II trial in advanced relapsed/refractory multiple myeloma (RMM) patients. Blood (2004) 104(11):63a-64a (Abstract).
103. RAJKUMAR SV, HAYMAN SR, LACY MQ et al.: Combination therapy with CC-5013 (lenalidomide; Revlimid™) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood (2004) 104(11):98a (Abstract).
104. SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of an immunomodulatory thalidomide analog CC-4047 in relapsed or refractory multiple myeloma. J. Clin. Oncol. (2004) 22(16):3269-3276.
105. ROUSSELOT P, LARGHERO J, ARNULF B et al.: A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia (2004) 18(9):1518-1521.